FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011375925> ?p ?o ?g. }

• W3011375925 endingPage "1092" @default.
• W3011375925 startingPage "1082" @default.
• W3011375925 abstract "Abstract Several functional parameters from baseline (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography have been proposed as promising biomarkers of treatment efficacy in diffuse large B-cell lymphoma (DLBCL). We tested their ability to predict outcome in 2 cohorts of DLBCL patients receiving conventional immunochemotherapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP] regimen), either every 14 (R-CHOP14) or 21 days (R-CHOP21). Baseline PET analysis was performed in 141 patients with DLBCL treated with R-CHOP14 in the prospective SAKK38/07 study (NCT00544219) of the Swiss Group for Clinical Cancer Research (testing set). Reproducibility was examined in a validation set of 113 patients treated with R-CHOP21. In the SAKK38/07 cohort, progression-free survival (PFS) at 5 years was 83% for patients with low metabolic tumor volume (MTV) and 59% for those with high MTV (hazard ratio [HR], 3.4; 95% confidence interval [CI], 1.6-7.0; P = .0005), whereas overall survival (OS) was 91% and 64%, respectively (HR, 4.4; 95% CI, 1.9-10; P = .0001). MTV was the most powerful predictor of outcome also in the validation set. Elevated metabolic heterogeneity (MH) significantly predicted poorer outcomes in the subgroups of patients with elevated MTV. A model integrating MTV and MH identified high-risk patients with shorter PFS (testing set: HR, 5.6; 95% CI, 1.8-17; P &lt; .0001; validation set: HR, 5.6; 95% CI, 1.7-18; P = .0002) and shorter OS (testing set: HR, 9.5; 95% CI, 1.7-52; P &lt; .0001; validation set: HR, 7.6; 95% CI, 2.0-28; P = .0003). This finding was confirmed by an unsupervised regression tree analysis indicating that prognostic models based on MTV and MH may allow early identification of refractory patients who might benefit from treatment intensification. This trial was registered at www.clinicaltrials.gov as #NCT00544219." @default.
• W3011375925 created "2020-03-23" @default.
• W3011375925 creator A5009234092 @default.
• W3011375925 creator A5010723896 @default.
• W3011375925 creator A5012537023 @default.
• W3011375925 creator A5012748128 @default.
• W3011375925 creator A5021191432 @default.
• W3011375925 creator A5024550101 @default.
• W3011375925 creator A5027984014 @default.
• W3011375925 creator A5044479977 @default.
• W3011375925 creator A5047468243 @default.
• W3011375925 creator A5048305396 @default.
• W3011375925 creator A5048622832 @default.
• W3011375925 creator A5050974067 @default.
• W3011375925 creator A5055401685 @default.
• W3011375925 creator A5057411375 @default.
• W3011375925 creator A5075117420 @default.
• W3011375925 creator A5082248258 @default.
• W3011375925 creator A5091441095 @default.
• W3011375925 date "2020-03-20" @default.
• W3011375925 modified "2023-10-10" @default.
• W3011375925 title "SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model" @default.
• W3011375925 cites W1020989877 @default.
• W3011375925 cites W1507619039 @default.
• W3011375925 cites W1646627486 @default.
• W3011375925 cites W1922216861 @default.
• W3011375925 cites W1968479659 @default.
• W3011375925 cites W1976020692 @default.
• W3011375925 cites W1982206371 @default.
• W3011375925 cites W2014254425 @default.
• W3011375925 cites W2037796411 @default.
• W3011375925 cites W2050115670 @default.
• W3011375925 cites W2054274023 @default.
• W3011375925 cites W2063563316 @default.
• W3011375925 cites W2063691874 @default.
• W3011375925 cites W2072351874 @default.
• W3011375925 cites W2075627595 @default.
• W3011375925 cites W2098488028 @default.
• W3011375925 cites W2101846955 @default.
• W3011375925 cites W2102472975 @default.
• W3011375925 cites W2111716055 @default.
• W3011375925 cites W2119147717 @default.
• W3011375925 cites W2122867074 @default.
• W3011375925 cites W2123998733 @default.
• W3011375925 cites W2129925362 @default.
• W3011375925 cites W2130929003 @default.
• W3011375925 cites W2131900456 @default.
• W3011375925 cites W2133201432 @default.
• W3011375925 cites W2134000437 @default.
• W3011375925 cites W2140485109 @default.
• W3011375925 cites W2141696740 @default.
• W3011375925 cites W2150587745 @default.
• W3011375925 cites W2158267770 @default.
• W3011375925 cites W2163363888 @default.
• W3011375925 cites W2166900358 @default.
• W3011375925 cites W2171356556 @default.
• W3011375925 cites W2275941472 @default.
• W3011375925 cites W2291210741 @default.
• W3011375925 cites W2343167264 @default.
• W3011375925 cites W2503562113 @default.
• W3011375925 cites W2507512417 @default.
• W3011375925 cites W2556592657 @default.
• W3011375925 cites W2591651461 @default.
• W3011375925 cites W2749123167 @default.
• W3011375925 cites W2782920912 @default.
• W3011375925 cites W2788217422 @default.
• W3011375925 cites W2797584152 @default.
• W3011375925 cites W2798083690 @default.
• W3011375925 cites W2800320119 @default.
• W3011375925 cites W2801726309 @default.
• W3011375925 cites W2801763724 @default.
• W3011375925 cites W2917357657 @default.
• W3011375925 cites W2927995861 @default.
• W3011375925 cites W2934192929 @default.
• W3011375925 cites W2963193255 @default.
• W3011375925 cites W2989546915 @default.
• W3011375925 cites W4205736005 @default.
• W3011375925 doi "https://doi.org/10.1182/bloodadvances.2019001201" @default.
• W3011375925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7094027" @default.
• W3011375925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32196557" @default.
• W3011375925 hasPublicationYear "2020" @default.
• W3011375925 type Work @default.
• W3011375925 sameAs 3011375925 @default.
• W3011375925 citedByCount "41" @default.
• W3011375925 countsByYear W30113759252020 @default.
• W3011375925 countsByYear W30113759252021 @default.
• W3011375925 countsByYear W30113759252022 @default.
• W3011375925 countsByYear W30113759252023 @default.
• W3011375925 crossrefType "journal-article" @default.
• W3011375925 hasAuthorship W3011375925A5009234092 @default.
• W3011375925 hasAuthorship W3011375925A5010723896 @default.
• W3011375925 hasAuthorship W3011375925A5012537023 @default.
• W3011375925 hasAuthorship W3011375925A5012748128 @default.
• W3011375925 hasAuthorship W3011375925A5021191432 @default.
• W3011375925 hasAuthorship W3011375925A5024550101 @default.
• W3011375925 hasAuthorship W3011375925A5027984014 @default.
• W3011375925 hasAuthorship W3011375925A5044479977 @default.
• W3011375925 hasAuthorship W3011375925A5047468243 @default.

• next